For research use only. Not for therapeutic Use.
Mitiglinide calcium is a Potassiun Channel blocker. Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells. Mitiglinide may be potential useful for the treatment of type 2 diabetes. Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs.
| Catalog Number | I007995 |
| CAS Number | 145525-41-3 (calcium) |
| Synonyms | KAD-1229; KAD 1229; KAD1229; S 21403; Mitiglinide calcium; Glufast.;calcium 2-benzyl-4-((3aR,7aS)-octahydro-2H-isoindol-2-yl)-4-oxobutanoate |
| Molecular Formula | C38H48CaN2O6 |
| Purity | ≥95% |
| Target | Potassium Channel |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| Reference | </br>1:Comparison Between Effectiveness of 100 mg/day Sitagliptin and a Switch to Mitiglinide Calcium Hydrate/Voglibose from 50 mg/day Sitagliptin in Patients with Type 2 Diabetes. Arao T, Okada Y, Torimoto K, Sugai K, Otsuka T, Kurozumi A, Tanaka Y.J UOEH. 2017;39(1):1-9. doi: 10.7888/juoeh.39.1. PMID: 28331117 Free Article</br>2:Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K.J Pharmacol Exp Ther. 2007 Jul;322(1):1-7. Epub 2007 Apr 4. PMID: 17409272 Free Article</br>3:[Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast), a new insulinotropic agent with rapid onset]. Ojima K, Kiyono Y, Kojima M.Nihon Yakurigaku Zasshi. 2004 Oct;124(4):245-55. Japanese. PMID: 15467258 </br>4:In vitro insulinotropic action of a new non-sulfonylurea hypoglycemic agent, calcium (2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinyl-carbonyl) propionate dihydrate (KAD-1229), in rat pancreatic B-cells. Ohnota H, Kobayashi M, Koizumi T, Katsuno K, Sato F, Aizawa T.Biochem Pharmacol. 1995 Jan 18;49(2):165-71. PMID: 7840793 </br>5:Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats. Ohnota H, Koizumi T, Kobayashi M, Momose Y, Sato F.Can J Physiol Pharmacol. 1995 Jan;73(1):1-6. PMID: 7600439 </br>6:Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S, Sato F.J Pharmacol Exp Ther. 1994 May;269(2):489-95. PMID: 8182516 |
.gif)